Cargando…
The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease
Ischemic cerebrovascular disease (ICD), the most common neurological disease worldwide, can be classified based on the onset time (acute/chronic) and the type of cerebral blood vessel involved (artery or venous sinus). Classifications include acute ischemic stroke (AIS)/transient ischemic attack (TI...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605177/ https://www.ncbi.nlm.nih.gov/pubmed/36294518 http://dx.doi.org/10.3390/jcm11206193 |
_version_ | 1784818000446095360 |
---|---|
author | Song, Siying Wu, Hao Ji, Xunming Meng, Ran |
author_facet | Song, Siying Wu, Hao Ji, Xunming Meng, Ran |
author_sort | Song, Siying |
collection | PubMed |
description | Ischemic cerebrovascular disease (ICD), the most common neurological disease worldwide, can be classified based on the onset time (acute/chronic) and the type of cerebral blood vessel involved (artery or venous sinus). Classifications include acute ischemic stroke (AIS)/transient ischemic attack (TIA), chronic cerebral circulation insufficiency (CCCI), acute cerebral venous sinus thrombosis (CVST), and chronic cerebrospinal venous insufficiency (CCSVI). The pathogenesis of cerebral arterial ischemia may be correlated with cerebral venous ischemia through decreased cerebral perfusion. The core treatment goals for both arterial and venous ICDs include perfusion recovery, reduction of cerebral ischemic injury, and preservation of the neuronal integrity of the involved region as soon as possible; however, therapy based on the current guidelines for either acute ischemic events or chronic cerebral ischemia is not ideal because the recurrence rate of AIS or CVST is still very high. Therefore, this review discusses the neuroprotective effects of four novel potential ICD treatments with high translation rates, known as the BE COOL treatments (Batroxobin, oxygEn, Conditioning, and cOOLing), and subsequently analyzes how BE COOL treatments are used in clinical settings. The combination of batroxobin, oxygen, conditioning, and cooling may be a promising intervention for preserving ischemic tissues. |
format | Online Article Text |
id | pubmed-9605177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96051772022-10-27 The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease Song, Siying Wu, Hao Ji, Xunming Meng, Ran J Clin Med Review Ischemic cerebrovascular disease (ICD), the most common neurological disease worldwide, can be classified based on the onset time (acute/chronic) and the type of cerebral blood vessel involved (artery or venous sinus). Classifications include acute ischemic stroke (AIS)/transient ischemic attack (TIA), chronic cerebral circulation insufficiency (CCCI), acute cerebral venous sinus thrombosis (CVST), and chronic cerebrospinal venous insufficiency (CCSVI). The pathogenesis of cerebral arterial ischemia may be correlated with cerebral venous ischemia through decreased cerebral perfusion. The core treatment goals for both arterial and venous ICDs include perfusion recovery, reduction of cerebral ischemic injury, and preservation of the neuronal integrity of the involved region as soon as possible; however, therapy based on the current guidelines for either acute ischemic events or chronic cerebral ischemia is not ideal because the recurrence rate of AIS or CVST is still very high. Therefore, this review discusses the neuroprotective effects of four novel potential ICD treatments with high translation rates, known as the BE COOL treatments (Batroxobin, oxygEn, Conditioning, and cOOLing), and subsequently analyzes how BE COOL treatments are used in clinical settings. The combination of batroxobin, oxygen, conditioning, and cooling may be a promising intervention for preserving ischemic tissues. MDPI 2022-10-20 /pmc/articles/PMC9605177/ /pubmed/36294518 http://dx.doi.org/10.3390/jcm11206193 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Song, Siying Wu, Hao Ji, Xunming Meng, Ran The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease |
title | The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease |
title_full | The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease |
title_fullStr | The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease |
title_full_unstemmed | The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease |
title_short | The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic Cerebrovascular Disease |
title_sort | be cool treatments (batroxobin, oxygen, conditioning, and cooling): emerging adjunct therapies for ischemic cerebrovascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605177/ https://www.ncbi.nlm.nih.gov/pubmed/36294518 http://dx.doi.org/10.3390/jcm11206193 |
work_keys_str_mv | AT songsiying thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT wuhao thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT jixunming thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT mengran thebecooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT songsiying becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT wuhao becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT jixunming becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease AT mengran becooltreatmentsbatroxobinoxygenconditioningandcoolingemergingadjuncttherapiesforischemiccerebrovasculardisease |